Wednesday, July 8, 2026

pharma · Pain · Hyponatremia · CPIX

Cumberland Pharmaceuticals

Cumberland Pharmaceuticals clinical programs — 19 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

1600 W End Ave, #1300, Nashville, Tennessee 37203, US HQ
1999 Founded
128 Employees
Public company Type
CPIX · NYSE Ticker
Company details
Status
Public
HQ
1600 W End Ave, #1300, Nashville, Tennessee 37203, US
Founded
1999
Employees
128
Programs
53
Drugs
26
Patents
34
Intelligence · Clinical Programs

Cumberland Pharmaceuticals projects

19 ClinicalTrials.gov programs sponsored by Cumberland Pharmaceuticals.

Cumberland Pharmaceuticals has 19 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 90 grams of Crystalline Lactulose

    CUMBERLAND PHARMACEUTICALS INC

    Colonoscopy Preparation

    phase 2 small molecule completed

    1 trial
  2. Atorvastatin injection

    CUMBERLAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial
  3. Crystalline Lactulose

    CUMBERLAND PHARMACEUTICALS INC

    Colonoscopy

    phase 2 small molecule completed

    1 trial
  4. Full dose preparation

    CUMBERLAND PHARMACEUTICALS INC

    Colonoscopy Preparation

    phase 2 small molecule completed

    1 trial
  5. Ifetroban

    CUMBERLAND PHARMACEUTICALS INC

    Portal Hypertension

    phase 2 small molecule completed

    1 trial
  6. Ifetroban

    CUMBERLAND PHARMACEUTICALS INC

    Duchenne Muscular Dystrophy Cardiomyopathy

    phase 2 small molecule completed

    1 trial
  7. Ifetroban Injection

    CUMBERLAND PHARMACEUTICALS INC

    Hepatorenal Syndrome

    phase 2 small molecule completed

    1 trial
  8. Ifetroban Oral Capsule

    CUMBERLAND PHARMACEUTICALS INC

    Asthma, Aspirin-Induced

    phase 2 small molecule completed

    1 trial
  9. Ifetroban Sodium

    CUMBERLAND PHARMACEUTICALS INC

    Cardiovascular Diseases

    phase 2 small molecule completed

    1 trial
  10. Ifetroban Sodium

    CUMBERLAND PHARMACEUTICALS INC

    Malignant Solid Tumor

    phase 2 small molecule active

    1 trial
  11. Ifetroban Sodium

    CUMBERLAND PHARMACEUTICALS INC

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial
  12. Ifetroban, Oral Capsule

    CUMBERLAND PHARMACEUTICALS INC

    Aspirin Exacerbated Respiratory Disease (AERD)

    phase 2 small molecule completed

    1 trial
  13. N-Acetylcysteine (NAC)

    CUMBERLAND PHARMACEUTICALS INC

    Radiocontrast Nephropathy

    phase 2 small molecule completed

    1 trial
  14. Oral Ifetroban

    CUMBERLAND PHARMACEUTICALS INC

    Scleroderma, Diffuse

    phase 2 small molecule active

    1 trial
  15. Telavancin

    CUMBERLAND PHARMACEUTICALS INC

    Gram-Positive Bacterial Infections

    phase 2 small molecule terminated

    2 trials
  16. Telavancin

    CUMBERLAND PHARMACEUTICALS INC

    Infections, Gram-Positive Bacterial

    phase 2 small molecule completed

    2 trials
  17. conivaptan

    CUMBERLAND PHARMACEUTICALS INC

    Liver Cirrhosis

    phase 2 small molecule completed

    1 trial
  18. conivaptan

    CUMBERLAND PHARMACEUTICALS INC

    Chronic Heart Failure

    phase 2 small molecule completed

    1 trial
  19. ranibizumab

    CUMBERLAND PHARMACEUTICALS INC

    Retinal Vein Occlusion

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Cumberland Pharmaceuticals have?

19 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.